➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Mallinckrodt
Colorcon
AstraZeneca
Express Scripts

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,344,006

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,344,006 protect, and when does it expire?

Patent 8,344,006 protects TREANDA and is included in one NDA.

Protection for TREANDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in eight countries.

Summary for Patent: 8,344,006
Title:Liquid formulations of bendamustine
Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.
Inventor(s): Drager; Anthony S. (Thorndale, PA), Labell; Rachel Y. (Coatesville, PA), Patel; Piyush R. (Wallingford, PA)
Assignee: Cephalon, Inc. (Frazer, PA)
Application Number:13/362,430
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Use;

Drugs Protected by US Patent 8,344,006

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cephalon TREANDA bendamustine hydrochloride SOLUTION;IV (INFUSION) 022249-003 Sep 13, 2013 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon TREANDA bendamustine hydrochloride SOLUTION;IV (INFUSION) 022249-004 Sep 13, 2013 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,344,006

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009296734   Start Trial
Australia 2015207940   Start Trial
Australia 2016203246   Start Trial
Australia 2016247123   Start Trial
Australia 2018202107   Start Trial
Canada 2735899   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Moodys
McKesson
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.